FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses the latest update on EYP-1901. The 8- and 9-month data from the phase 1 DAVIO trial of EYP-1901 for the treatment of wet age-related macular degeneration showed very good safety and efficacy, according to Lurker.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses the latest update on EYP-1901. The 8- and 9-month data from the phase 1 DAVIO trial of EYP-1901 for the treatment of wet age-related macular degeneration showed very good safety and efficacy, according to Lurker.
